Christine Ulrich
Family · van Wert, OHNPI 1619955754
Payments from drug & device makers
Across 405 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$975
- Lilly USA, LLC$539
- Amgen$423
- AstraZeneca$314
- Axsome Therapeutics, Inc.$257
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,73199%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 155 | $1,576 |
| Novo Nordisk | 72 | $975 |
| Lilly USA, LLC | 33 | $539 |
| Amgen | 17 | $423 |
| AstraZeneca | 9 | $314 |
| Axsome Therapeutics, Inc. | 14 | $257 |
| Nestle Healthcare Nutrition Inc. | 17 | $215 |
| Indivior Inc. | 7 | $197 |
| Sanofi-aventis U.S. LLC | 16 | $180 |
| Bayer | 6 | $93 |
| Aimmune Therapeutics, Inc. | 5 | $79 |
| Lucid Diagnostics Inc. | 2 | $77 |
| Mannkind Corporation | 2 | $65 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $65 |
| Pfizer | 4 | $56 |
| Johnson & Johnson | 4 | $56 |
| Exact Sciences | 3 | $56 |
| Sumitomo Pharma America, Inc. | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Merck | 3 | $45 |
| GSK | 2 | $36 |
| Braeburn Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Medtronic | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| UCB, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Abbott | 1 | $15 |
| Novartis | 1 | $15 |
| Harmony Biosciences LLC | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,773 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $116,381 |
| MounjaroTirzepatide | 87 | $93,108 |
| RybelsusSemaglutide | 34 | $64,105 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 51 | $53,253 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $44,978 |
| JardianceEmpagliflozin | 35 | $42,430 |
| EliquisApixaban | 44 | $41,706 |
| FarxigaDapagliflozin Propanediol | 22 | $27,899 |
| MyrbetriqMirabegron | 34 | $24,701 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $21,241 |
| TrulicityDulaglutide | 17 | $18,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $18,175 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $16,571 |
| GemtesaVibegron | 11 | $13,232 |
| XareltoRivaroxaban | 11 | $12,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $975 | $180,485134 claims |
| Lilly USA, LLCMounjaro, Trulicity | $539 | $111,687104 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $180 | $53,25351 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $314 | $49,14049 claims |
| Boehringer IngelheimJardiance | $31 | $42,43035 claims |
| PfizerEliquis | $56 | $41,70644 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $24,70134 claims |
| GSKTrelegy Ellipta | $36 | $18,17524 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $55 | $13,23211 claims |
| Johnson & JohnsonXarelto | $56 | $12,07011 claims |
| AbbVieSynthroid | $1,576 | $1,26231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in van Wert
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.